胰高血糖素样肽-1受体激动剂调节2型糖尿病糖脂代谢研究进展被引量：6

Review on effects of GLP-1 receptor agonists on lipid metabolism in type 2 diabetes mellitus

导出

摘要胰高血糖素样肽-1(glucagon-like peptide-1,GLP-1)受体激动剂类药物是一类新型抗糖尿病药物,可呈血糖依赖性地促进胰岛素的分泌、减慢胃排空、增加外周组织对葡萄糖的摄取,从而起到控制血糖的作用。本文对GLP-1受体激动剂近年来的国内外文献进行综述,从其对血糖、血脂及体质量等方面的影响展开分析,并比较了不同GLP-1受体激动剂之间,及与其他降糖药物之间的疗效差异,旨在阐明此类药物在改善2型糖尿病代谢方面的作用特点。 Glucagon-like peptide-I （GLP-I） receptor agonists are new type of antidiabetic medicines that have multiple glucoregulatory effects including enhanced glucose dependent insulin secretion, slowing of gastric emptying and increasing glucose uptake in peripheral tissues. In this paper, the recent literatures about the GLP-1 receptor agonists both at home and abroad were summarized to evaluate their impact on blood glucose, blood lipid and body weight. The efficacy of different GLP-1 receptor agonists and other antidiabetic medicines were also compared in type 2 diabetes mellitus. The main aim of the review is to elucidate the effect of GLP-1 receptor agonists on the lipid metabolisms in patients with type 2 diabetes mellitus.

作者李玲于文君严妍李蕊李妍

机构地区山东大学药学院山东省千佛山医院药学部

出处《中国医院药学杂志》 CAS 北大核心 2017年第10期991-995,共5页 Chinese Journal of Hospital Pharmacy

基金山东省自然科学基金(编号:ZR2010HL017) 济南市科技局项目(编号:201602171)

关键词胰高血糖素样肽-1受体激动剂 2型糖尿病降糖药物临床研究 glucagon-like peptide-1 receptor agonists type 2 diabetes mellitus antidiabetic medicines clinical trial

分类号 R96 [医药卫生—药理学]

引文网络
相关文献

参考文献1

1王伟夫,胡欣.利拉鲁肽的临床研究进展[J].中国医院药学杂志,2012,32(24):2003-2005. 被引量：3

二级参考文献21

1Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China[J]. N Engl J Med, 2010,362 (12) : 1090-101.
2Stratton IM, Adler AI, Neil HA, etal. Association of glycae- nfia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study[J]. BMJ, 2000,321 (7258) :405-12.
3Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-I receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes[J]. Lancet, 2006,368(9548) : 1696-705.
4Deacon CF, Nauck MA, Toft Nielsen M, et al. Both subcuta neously and intravenously administered glucagon like peptide 1 are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects[J]. Diabetes, 1995, 44 (9) : 1126-31.
5Nauck M, Smith U. lncretin based therapy: how do incretin mimetics and DPP4 inhihitors fit into treatment algorithms for type 2 diabetic patients? [J]. Best Pract Res Clin Endocrinol Met ab, 2009,23 (4) : 513-23.
6Davies MJ, Kela R, Khunti K. Liraglutide - overview of the preclinical and clinical data and its role in the lreatment of type 2 diabetes[J]. Diabetes Obes Metab, 2011,13(3):207-20.
7Vilsboll T. Liraglutide: a once-daily GLP 1 analogue for the treatment of type 2 diabetes mellitus[J]. Expert Opin Investig Drugs, 2007,16(2) :231-7.
8Elbrond B, Jakobsen G, Larsen S, et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long acting glucagon-like peptide 1 derivative, in healthy male subjects[J]. Diabetes Care, 2002,25 (8) :1398- 404.
9Jiang J, Zhang J, Jacobsen LV, et al. The Pharmacokinetics,Pharmacodynamics, and Tolerability of Liraglutide, a Onee Daily Human GLbl Analogue, Afler MuLtiple Subcutaneous Administration in Healthy Chinese Male Subjects[J]. J Clin Pharmacol, 2011 ,51(12):1620- 7.
10Bust JB, Rosenstock J, Scsti G, et at. Liraglutidc once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomiscd, parallel-group, multinational, open-label trial (LEAD-6) [J]. Lancet, 2009,374(9683) :39 -47.